Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced

Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase
1 Trial of GR-MD-02 for NASH With Advanced Fibrosis

NORCROSS, Ga., April 17, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics
(Nasdaq:GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, announced today that the first patient
in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH
with advanced fibrosis has been successfully dosed with 4 mg/kg, which is
double the dose given in cohort 1. Cohort 2, as with all phases of the
clinical trial, was initiated in full compliance with the rules, regulations,
and specific conditions set forth by the U.S. Food and Drug Administration
(FDA) for this Phase 1 clinical trial. The second cohort follows highly
successful results from the first cohort showing that 2 mg/kg was safe and
very well tolerated, and that GR-MD-02 treatment resulted in significant
improvement in multiple biomarkers of fibrosis and liver inflammation in
patients with NASH with advanced fibrosis (see full results:
The remaining patients in cohort 2 are expected to be enrolled over the next
few weeks and we anticipate reporting the results of cohort 2 around the end
of July.

"We were extremely pleased with the results of the first cohort, which
demonstrated significant biomarker effects on fibrosis and inflammation in all
the patients treated with GR-MD-02, coupled with good safety and
tolerability," said Dr. Peter G. Traber, President, Chief Executive Officer,
and Chief Medical Officer of Galectin Therapeutics Inc. "These positive
results have propelled the enrollment of the second cohort with strong
participation across our clinical trial sites. We anticipate the cohort 2
results will further support the use of GR-MD-02 in patients with NASH and
advanced fibrosis, with the goal of reversing fibrosis and preventing
complications of cirrhosis and liver transplantation."

The trial is titled "A Multi-Center, Partially Blinded, Maximum Tolerated
Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of
GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced
Hepatic Fibrosis." Trial design details can be found at In 2013,
Galectin Therapeutics received Fast Track designation from the FDA for this
clinical development program. FDA grants Fast Track designation to help
expedite review and approval of drugs in development that treat serious or
life threatening diseases and fill an unmet medical need.

About Fatty Liver Disease with Advanced Fibrosis

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has
become a common disease of the liver with the rise in obesity rates, estimated
to affect nine to 15 million people, including children, in the U.S. Fatty
liver disease is characterized by the presence of fat in the liver along with
inflammation and damage in people who drink little or no alcohol. Over time,
patients with fatty liver disease can develop fibrosis, or scarring of the
liver, and it is estimated that as many as three million individuals will
develop cirrhosis, a severe liver disease where liver transplantation is the
only current treatment available. Approximately 6,300 liver transplants are
done on an annual basis in the U.S. There are no drug therapies approved for
the treatment of liver fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development expertise as
well as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear development
pathway to clinical enhancement and commercialization for our lead compounds
in liver fibrosis and cancer. Additional information is available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"anticipated," "expect" and others. They are based on our current expectations
and are subject to factors and uncertainties, which could cause actual results
to differ materially from those described in the statements. These statements
include those regarding the clinical trial, including the expected timing of
results for the second cohort, and potential benefits and therapeutic effects
of GR-MD-02. Factors that could cause our actual performance to differ
materially from those discussed in the forward-looking statements include,
among others, that we may not be successful in developing effective treatments
and/or obtaining the requisite approvals for the use of GR-MD-02 or any of our
other drugs in development. Our current clinical trial and any future clinical
studies may not produce positive results in a timely fashion, if at all, and
could prove time consuming and costly. We may have difficulty enrolling new
patients, which could impact timing and costs. Results from the first cohort
of Phase 1 are not necessarily indicative of future results in the clinical
trial.Plans regarding development, approval and marketing of any of our drugs
are subject to change at any time based on the changing needs of our company
as determined by management and regulatory agencies. Regardless of the results
of any of our development programs, we may be unsuccessful in developing
partnerships with other companies that would allow us to further develop
and/or fund any studies or trials.To date, we have incurred operating losses
since our inception, and our ability to successfully develop and market drugs
may be impacted by our ability to manage costs and finance our continuing
operations. For a discussion of additional factors impacting our business, see
our Annual Report on Form 10-K for the year ended December 31, 2013, and our
subsequent filings with the SEC. You should not place undue reliance on
forward-looking statements. Although subsequent events may cause our views to
change, we disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO & CMO

Galectin Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.